| Year |
Title |
Altmetric |
| 2021
|
Reply.
Journal of Pediatrics.
230:277-278.
2021
|
|
| 2018
|
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.
Bone Marrow Transplantation.
53:1345-1348.
2018
|
|
| 2018
|
Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab
2018
|
|
| 2016
|
A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.
Advances in Radiation Oncology.
1:83-88.
2016
|
|
| 2016
|
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy..
Journal of Nuclear Medicine.
57:151-162.
2016
|
|
| 2014
|
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
Journal of Nuclear Medicine.
55:1636-1642.
2014
|
|
| 2014
|
MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations.
Journal of Nuclear Medicine.
55:1557-1564.
2014
|
|
| 2014
|
Pazopanib combined with radiation: In vivo model of interaction.
Cancer Biotherapy and Radiopharmaceuticals.
29:247-250.
2014
|
|
| 2014
|
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
Cancer Biotherapy and Radiopharmaceuticals.
29:12-17.
2014
|
|
| 2013
|
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.
Journal of Nuclear Medicine.
54:2182-2188.
2013
|
|
| 2013
|
Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphoma.
Cancer Biotherapy and Radiopharmaceuticals.
28:370-379.
2013
|
|
| 2013
|
Multiple myeloma, version 1.2013: Featured updates to the NCCN guidelines
2013
|
|
| 2012
|
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013: Featured updates to the NCCN guidelines
2012
|
|
| 2012
|
Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Cancer Biotherapy and Radiopharmaceuticals.
27:36-40.
2012
|
|
| 2011
|
Multiple myeloma clinical practice guidelines in oncology
2011
|
|
| 2011
|
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
Cancer Biotherapy and Radiopharmaceuticals.
26:127-133.
2011
|
|
| 2010
|
Renal dosimetry.
Cancer Biotherapy and Radiopharmaceuticals.
25:597-599.
2010
|
|
| 2010
|
Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer.
Clinical Breast Cancer.
10:275-280.
2010
|
|
| 2010
|
Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
2010
|
|
| 2010
|
MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy.
Journal of Nuclear Medicine.
51:311-328.
2010
|
|
| 2010
|
Impact of Dose Rate on Outcomes of Gamma Knife® Radiosurgery in Patients with Face Pain.
Radiosurgery.
7:360-365.
2010
|
|
| 2010
|
Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Journal of Nuclear Medicine.
51:150-157.
2010
|
|
| 2010
|
Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer
2010
|
|
| 2009
|
Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving Radiation Therapy With or Without Chemotherapy.
Journal of Pain and Symptom Management.
38:522-532.
2009
|
|
| 2009
|
Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source..
Journal of Applied Clinical Medical Physics.
10:2903.
2009
|
|
| 2009
|
MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for 111In-And 90Y-ibritumomab Tiuxetan.
Journal of Nuclear Medicine.
50:644-652.
2009
|
|
| 2009
|
MIRD commentary: Proposed name for a dosimetry unit applicable to deterministic biological effects-the barendsen (Bd).
Journal of Nuclear Medicine.
50:485-487.
2009
|
|
| 2009
|
MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature.
Journal of Nuclear Medicine.
50:477-484.
2009
|
|
| 2009
|
Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer
2009
|
|
| 2009
|
Cancer of the tonsil presenting as central nervous system metastasis: A case report
2009
|
|
| 2009
|
Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source.
Journal of Applied Clinical Medical Physics.
10:90-102.
2009
|
|
| 2009
|
Multiple myeloma
2009
|
|
| 2008
|
MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response - Implications for radionuclide therapy.
Journal of Nuclear Medicine.
49:1884-1899.
2008
|
|
| 2008
|
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Journal of Clinical Oncology.
26:2489-2496.
2008
|
|
| 2008
|
Risks to Normal Tissues From Radionuclide Therapy.
Seminars in Nuclear Medicine.
38:347-357.
2008
|
|
| 2008
|
Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment
2008
|
|
| 2008
|
Targeted radionuclide therapy..
Medical Physics.
35:3062-3068.
2008
|
|
| 2008
|
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck
2008
|
|
| 2008
|
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.
Journal of Nuclear Medicine.
49:279-284.
2008
|
|
| 2008
|
Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone
2008
|
|
| 2008
|
Targeted radionuclide therapy.
Medical Physics.
35:3062-3068.
2008
|
|
| 2007
|
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical Cancer Research.
13.
2007
|
|
| 2007
|
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
2007
|
|
| 2007
|
Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03
2007
|
|
| 2007
|
Microvessel density ≥60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: Results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 trial
2007
|
|
| 2007
|
Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire.
Cancer.
109:1914-1922.
2007
|
|
| 2006
|
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy
2006
|
|
| 2006
|
Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
2006
|
|
| 2006
|
Logistics of therapy with the ibritumomab tiuxetan regimen
2006
|
|
| 2006
|
Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma
2006
|
|
| 2006
|
Overview of dosimetry for systemic targeted radionuclide therapy (STaRT)
2006
|
|
| 2006
|
Pretargeted radioimmunotherapy
2006
|
|
| 2006
|
Summary of systemic targeted radionuclide therapy symposium
2006
|
|
| 2006
|
Systemic Targeted Radionuclide Therapy symposium introduction
2006
|
|
| 2006
|
Effect of pilocarpine during radiation therapy: Results of RTOG 97-09, a phase III randomized study in head and neck cancer patients
2006
|
|
| 2006
|
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Journal of Nuclear Medicine.
47:534-542.
2006
|
|
| 2005
|
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Journal of Nuclear Medicine.
46:642-651.
2005
|
|
| 2005
|
Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration.
Cancer Biotherapy and Radiopharmaceuticals.
20:467-478.
2005
|
|
| 2005
|
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Cancer Biotherapy and Radiopharmaceuticals.
20:379-390.
2005
|
|
| 2005
|
Clinically useful marrow dosimetry for targeted radionuclide therapy.
Cancer Biotherapy and Radiopharmaceuticals.
20:119-122.
2005
|
|
| 2005
|
Testicular uptake and radiation dose in patients receiving Zevalin™ and Pretarget™ CC49Fusion protein.
Cancer Biotherapy and Radiopharmaceuticals.
20:110-118.
2005
|
|
| 2004
|
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison.
Journal of Nuclear Medicine.
45:1725-1733.
2004
|
|
| 2004
|
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Blood.
104:227-236.
2004
|
|
| 2003
|
P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003
2003
|
|
| 2003
|
Phase III quality-of-life study results: Impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 97-09
2003
|
|
| 2003
|
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer
2003
|
|
| 2003
|
A Novel Monoclonal Antibody Design for Radioimmunotherapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:751-759.
2003
|
|
| 2003
|
Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:393-404.
2003
|
|
| 2003
|
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:209-215.
2003
|
|
| 2002
|
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy.
Journal of Nuclear Medicine.
43:1245-1253.
2002
|
|
| 2002
|
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: Long-term follow-up of a phase I trial.
Lung Cancer.
37:189-199.
2002
|
|
| 2002
|
Model prediction of treatment planning for dose-fractionated radioimmunotherapy..
Cancer.
94:1264-1269.
2002
|
|
| 2002
|
Rationales, evidence, and design considerations for fractionated radioimmunotherapy..
Cancer.
94:1332-1348.
2002
|
|
| 2002
|
A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical Cancer Research.
8:2806-2811.
2002
|
|
| 2001
|
Radioimmunotherapy of B-cell NHL.
Current Pharmaceutical Biotechnology.
2:327-339.
2001
|
|
| 2001
|
RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck
2001
|
|
| 2001
|
Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study.
Cancer Biotherapy and Radiopharmaceuticals.
16:305-315.
2001
|
|
| 2001
|
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
Journal of Clinical Oncology.
19:3234-3243.
2001
|
|
| 2000
|
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers..
Journal of Clinical Oncology.
18:47S-53S.
2000
|
|
| 2000
|
Clinical radioimmunotherapy.
Seminars in Radiation Oncology.
10:73-93.
2000
|
|
| 1999
|
A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy..
Clinical Cancer Research.
5:3044s-3047s.
1999
|
|
| 1999
|
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer..
Clinical Cancer Research.
5:3254s-3258s.
1999
|
|
| 1999
|
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck
1999
|
|
| 1999
|
Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation.
Cancer Biotherapy and Radiopharmaceuticals.
14:451-463.
1999
|
|
| 1998
|
Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177Lu-CC49.
Minerva Biotechnologica.
10:100-107.
1998
|
|
| 1998
|
Chimeric antibodies with specificity for tumor antigens: Demonstration of in situ localization to tumors after antibody therapy
1998
|
|
| 1997
|
Recent Progress in Radioimmunotherapy for Cancer
1997
|
|
| 1997
|
Sucralfate for radiation mucositis: Results of a double-blind randomized trial
1997
|
|
| 1997
|
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
Cancer Biotherapy and Radiopharmaceuticals.
12:79-87.
1997
|
|
| 1997
|
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study.
Gynecologic Oncology.
65:94-101.
1997
|
|
| 1996
|
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
Clinical Cancer Research.
2:1811-1818.
1996
|
|
| 1996
|
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49.
Journal of Nuclear Medicine.
37:1491-1496.
1996
|
|
| 1996
|
Major geometric variations between intracavitary applications in carcinoma of the cervix: High dose rate vs. Low dose rate
1996
|
|
| 1996
|
Postsurgical recurrent carcinoma of the cervix: Reassessment and results of radiation therapy options.
Radiology.
201:559-563.
1996
|
|
| 1995
|
Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.
Journal of Nuclear Medicine.
36:2229-2233.
1995
|
|
| 1995
|
Fractionated radioimmumotherapy of human colon carcinoma xenografts with131I-labeled monoclonal antibody CC49.
Cancer Research.
55.
1995
|
|
| 1995
|
Conventional four-field pelvic radiotherapy technique without computed tomography-treatment planning in cancer of the cervix: Potential geographic miss and its impact on pelvic control
1995
|
|
| 1995
|
Major geometric variations between multiple high-dose-rate applications of brachytherapy in cancer of the cervix: Frequency and types of variation.
Radiology.
195:419-422.
1995
|
|
| 1994
|
Conventional four-field pelvic radiotherapy technique without CT treatment planning in cancer of the cervix: potential geographic miss.
Radiotherapy and Oncology.
30:140-145.
1994
|
|
| 1994
|
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
Journal of Nuclear Medicine.
35:1017-1022.
1994
|
|
| 1993
|
Malignant epidural spinal cord compression associated with a paravertebral mass: Its radiotherapeutic outcome on radiosensitivity
1993
|
|
| 1993
|
A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Cancer biotherapy.
8:3-16.
1993
|
|
| 1993
|
Comparison of diagnostic and therapeutic doses of 131I-LYM-1 in patients with non-Hodgkin's lymphoma.
Antibody, Immunoconjugates, and Radiopharmaceuticals.
6:1-11.
1993
|
|
| 1993
|
Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
Human Antibodies.
4:190-197.
1993
|
|
| 1993
|
Dosimetry of solid tumors.
Medical Physics.
20:583-592.
1993
|
|
| 1993
|
Effect of Human immune response on repeat courses of 131I-Chimeric B72.3 antibody therapy.
Antibody, Immunoconjugates, and Radiopharmaceuticals.
6:39-46.
1993
|
|
| 1992
|
A Phase I study of high-dose cisplatin, prolonged infusion 5- fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck
1992
|
|
| 1992
|
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
Journal of Nuclear Medicine.
33:1648-1653.
1992
|
|
| 1992
|
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.
Journal of Nuclear Medicine.
33:23-29.
1992
|
|
| 1992
|
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation
1992
|
|
| 1991
|
Pharmacokinetics and Immune Response of 131I-ChimericMouse/Human B72.3 (Human 74) Monoclonal Antibody in Humans.
Cancer Research.
51:5461-5466.
1991
|
|
| 1991
|
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck
1991
|
|
| 1991
|
Expedient set-up of tangential breast fields with a simple gantry attachment
1991
|
|
| 1991
|
Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.
Journal of Nuclear Medicine.
32:1162-1168.
1991
|
|
| 1991
|
Three-port perineal sparing technique.
Radiology.
180:563-566.
1991
|
|
| 1990
|
Extradural spinal cord compression: Analysis of factors determining functional prognosis - Prospective study.
Radiology.
176:279-282.
1990
|
|
| 1990
|
Hyperthermia of pet animal tumours with self-regulating ferromagnetic thermoseeds.
International Journal of Hyperthermia.
6:117-130.
1990
|
|
| 1990
|
The changing face of radiation oncology.
Southern Medical Journal.
83:488.
1990
|
|
| 1989
|
Ferromagnetic thermoseeds: Suitable for an afterloading interstitial implant
1989
|
|
| 1989
|
Practical aspects of ferromagnetic thermoseed hyperthermia.
Radiologic Clinics of North America.
27:589-602+ix.
1989
|
|
| 1987
|
1986 Association of residents in radiation oncology survey
1987
|
|
| 1986
|
An excess of uterine sarcomas after pelvic irradiation..
Cancer.
58:2003-2007.
1986
|
|
| 1986
|
Beta-chain human chorionic gonadotropin-producing leiomyosarcoma of the small intestine..
Cancer.
58:131-135.
1986
|
|
| 1986
|
An excess of uterine sarcomas after pelvic irradiation.
Cancer.
58:2003-2007.
1986
|
|
| 1986
|
Beta‐chain human chorionic gonadotropin‐producing leiomyosarcoma of the small intestine.
Cancer.
58:131-135.
1986
|
|
| 1983
|
Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation.
Transplantation.
35:378-385.
1983
|
|
| 1982
|
Possibility of three distinct and separable components to fatal graft-vs-host reaction.
Experimental Hematology.
10:277-291.
1982
|
|
| 1982
|
Effects of piperazinedione (NSC 135785) plus irradiation on endogenous CFU-S, intestinal crypts, and as a possible ablative protocol for marrow transplantation as evaluated in Rauscher leukemic mice.
Radiation Research.
89:559-574.
1982
|
|
| 1981
|
Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia.
Experimental Hematology.
9:754-765.
1981
|
|
| 1981
|
Histocompatibility influence in allogeneic marrow transplantation therapy of murine viral leukemia. I.--Studies of the relative influence of major versus minor histocompatibility determinants..
Biomedicine / [publiee pour l'A.A.I.C.I.G.].
34:11-17.
1981
|
|
| 1981
|
Fatal response suggestive of graft-versus-host reaction following transplantation of spleen cells from allogeneic athymic (Nude) donors.
Transplantation.
31:201-204.
1981
|
|
| 1980
|
Methyl methane sulfonate induced enhancement of Friend viral leukemogenesis.
Experientia.
36:337-338.
1980
|
|
| 1980
|
Exponential relationship between spleen cell concentration and fatal graft-versus-host response after transplantation of allogeneic spleen-marrow cell mixtures.
Transplantation.
29:507-510.
1980
|
|
| 1980
|
Rauscher Leukemia as a Model for Cancer Therapy Studies. II. Variation in Response of Splenic CFU-S between Normal and Rauscher Leukemic Mice following Exposure to Hydroxyurea
1980
|
|
| 1979
|
Cyclophosphamide/X-ray: Combined mode preparation for transplantation therapy
1979
|
|
| 1979
|
Effect of piperazinedione (NSC 135758) and irradiation combined treatment on stem cell populations in normal and leukemic mice.
Proceedings of the American Association for Cancer Research.
Vol. 20.
1979
|
|
| 1979
|
Improving transplantation therapy of leukemia: A new model for testing marrow ablative pretreatments.
Proceedings of the American Association for Cancer Research.
Vol. 20:341.
1979
|
|
| 1979
|
Potentiating Effect of Methyl Methane Sulfonate on Friend Virus Leukemogenesis in Vivo
1979
|
|
| 1979
|
Rauscher leukemia as a model for studies of marrow transplantation therapy: Results using syngeneic, allogeneic and hybrid donors.
International Journal of Cancer.
24:438-444.
1979
|
|
| 1978
|
Successful therapy of viral leukemia by transplantation of histocompatibility unmatched marrow.
Experimental Hematology.
6:273-282.
1978
|
|
| 1978
|
Comparison of cyclophosphamide and/or X irradiation in the preparation of viral leukemic mice for marrow transplantation therapy.
Radiation Research.
74.
1978
|
|
| 1978
|
Contrasting immune response following Rauscher leukemia virus infection in virus-susceptible vs. virus-resistant mice.
Developmental and Comparative Immunology.
2:133-146.
1978
|
|
| 1978
|
Stimulation of Immune Response in Hybrid Mice Following Rauscher Virus Infection
1978
|
|
| 1976
|
Genetic influence in murine viral leukemogenesis.
Biomedicine.
24:374-380.
1976
|
|
| 1975
|
THE GENETIC BASIS OF MALE POTENCY IN VOLVOX CARTERI F. NAGARIENSIS (CHLOROPHYCEAE)
1975
|
|
